Actively Recruiting

Phase Not Applicable
Age: 55Years - 90Years
All Genders
ID07239310

Neuclare Device to Improve Executive Function in Adults With Mild Cognitive Impairment and Early Alzheimer's Disease: A Multicenter, Randomized, Double-Blind Clinical Trial

Led by Deepsonbio · Updated on 2025-12-10

138

Participants Needed

3

Research Sites

4 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating the Neuclare medical device to see if it can temporarily improve executive functions like planning and problem-solving in adults with mild cognitive impairment or very early Alzheimer's disease. This confirmatory clinical trial is conducted at multiple centers and is randomized, double-blind, and parallel-group in design. Participants continue their usual cognitive medications during the study. Participants are randomly assigned to receive either the Neuclare device or a sham device as a control. Both groups continue their standard medication. The device is applied to the brain three times a week for four weeks, with each session lasting less than 30 minutes. The study staff and participants do not know which treatment is given to ensure unbiased results. Throughout the trial, participants undergo assessments including attention, cognitive function, daily living activities, brain imaging with Amyloid PET-CT, blood biomarker testing, and quality of life questionnaires. Safety and any adverse events are carefully monitored. The primary measure is the change in time to complete the Trail Making Test-A from baseline to five weeks. The study ends in July 2026.

CONDITIONS

Brief Title

Neuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease

Who Can Participate

Age: 55Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 55 to 90 years
  • Diagnosed with probable Alzheimer's disease or mild cognitive impairment with CDR 0.5-1 and MMSE-II ≥18
  • On stable cognitive therapy medications for at least 1 month
  • Voluntary participation with signed informed consent
Not Eligible

You will not qualify if you...

  • Structural brain lesions detected on MRI (e.g., edema, hemorrhage, infarction, tumor)
  • Uncontrolled metabolic disorders or long-term medications causing cognitive impairment
  • History of epileptic seizures, depression, psychiatric disorders, visual hallucinations, or fluctuating cognitive decline
  • Severe diseases such as cancer or tuberculosis
  • Use of psychoactive drugs affecting the nervous system
  • Contact dermatitis or skin hypersensitivity
  • Fever ≥ 40°C by tympanic measurement
  • Recent bleeding within past 3 months from procedures or surgeries
  • Unable to undergo MRI
  • Pregnancy
  • Brain calcification seen on CT
  • Known allergies to contrast agents like Definity or Gadovist
  • Any condition deemed inappropriate by the investigator for participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - 4 weeks

Participants receive the Neuclare device or a sham device applied to the cerebral cortex with low-intensity ultrasound stimulation less than 30 minutes per session, three times per week for 4 weeks while continuing their cognitive medication.

Up to 12 visits (3 visits per week for 4 weeks, in-person)

Trial Site Locations

Total: 3 locations

1

Hallym University Dongtan Sacred Heart Hospital

Hwaseong-si, Gyeonggi-do, South Korea, 18450

Not Yet Recruiting

2

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea, 13620

Actively Recruiting

3

Ewha Womans University Mokdong Hospital

Seoul, South Korea, 07985

Actively Recruiting

Loading map...

Research Team

S

Sung Kyung Lee

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Phase I Study to Assess the Safety, Tolerability and Preli...

Alzheimer's Disease

Actively Recruiting

2 locations

A Feasibility Study of Green Activity Program for People Liv...

Mild Cognitive Impairment

Actively Recruiting

1 location

A Novel Multi-Modal Approach to Promote Functional Outcomes ...

Frailty at Older Adults

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here